Emergent BioSolutions Stock Price and Value Analysis

Should you buy Emergent BioSolutions stock? (NYSE:EBS). Let's see how it does in our automated value investing analysis system.

EBS Free Cash Flow Trend

Free Cash Flow trendline for EBS
Free Cash Flow trendline for Emergent BioSolutions

Hmm, we can't give any reliable projection for Emergent BioSolutions's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company is solid.
  • This company is not making money.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the EBS Numbers

EBS Price
(Emergent BioSolutions stock price per share)
[?] PE Ratio versus Sector 183% higher than other Healthcare stocks
[?] PE Ratio versus Industry 6% lower than other Unknown stocks
[?] Cash Yield 0.90%
[?] Free Cash Flow Jitter 406%

Is Emergent BioSolutions Stock on Sale?

Based on our analysis, we believe that you should not buy Emergent BioSolutions right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy EBS Stock?

Does Emergent BioSolutions have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.